Windtree Therapeutics Delists from Nasdaq: What You Need to Know

Nasdaq has announced that Windtree Therapeutics will be delisted from the exchange, effective August 21, 2025. This decision comes due to the company failing to meet the minimum bid price requirement outlined by Nasdaq Listing Rule 5550(a)(2), which mandates a minimum share price of $1. The delisting signifies that Windtree’s shares will shift to trading on the OTC market, pending OTCID approval. While this move impacts Windtree’s stock liquidity and investor confidence, it is not expected to have significant repercussions on major cryptocurrencies or DeFi markets.